3 reports of this reaction
0.9% of all BENZETHONIUM CHLORIDE reports
#19 most reported adverse reaction
ALANINE AMINOTRANSFERASE INCREASED is the #19 most commonly reported adverse reaction for BENZETHONIUM CHLORIDE, manufactured by McKesson. There are 3 FDA adverse event reports linking BENZETHONIUM CHLORIDE to ALANINE AMINOTRANSFERASE INCREASED. This represents approximately 0.9% of all 326 adverse event reports for this drug.
Patients taking BENZETHONIUM CHLORIDE who experience alanine aminotransferase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALANINE AMINOTRANSFERASE INCREASED is a less commonly reported adverse event for BENZETHONIUM CHLORIDE, but still significant enough to appear in the safety profile.
In addition to alanine aminotransferase increased, the following adverse reactions have been reported for BENZETHONIUM CHLORIDE:
The following drugs have also been linked to alanine aminotransferase increased in FDA adverse event reports:
ALANINE AMINOTRANSFERASE INCREASED has been reported as an adverse event in 3 FDA reports for BENZETHONIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALANINE AMINOTRANSFERASE INCREASED accounts for approximately 0.9% of all adverse event reports for BENZETHONIUM CHLORIDE, making it a notable side effect.
If you experience alanine aminotransferase increased while taking BENZETHONIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.